| Data Sharing Statement | | |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article Info | https://dx.doi.org/10.21037/tcr-22-106 | |
| Item | Question | Authors' Response (place "-" if not applicable) |
| 1 | Would you like to share data collected for your study to others? | Yes |
| 2 | If not, would you like to share the reason for your decision? | _ |
| 3 | What data in particular will be shared? | Our prediction model data in particular will be shared, because we further validate our models in four additional independent datasets and the merged data set. This suggests that our model was stable and reliable. |
| 4 | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan will also be shared if requested. |
| 5 | When will data availability begin? | From the publication date. |
| 6 | When will data availability end? | Two years within the publication date, since the technique or survival data may be updated over time. |
| 7 | To whom will you share the data? | Medical oncologists who are interested in studies of gene signature. |
| 8 | For what type of analysis or purpose? | For analysis to predict LUAD prognosis. |
| 9 | How or where can the data/documents be obtained? | Emails could be sent to the address below to obtain the shared data: 201901145@hrbmu.edu.cn |
| 10 | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |